Obesity 

Intro: This study will compare injectable medications in various doses to placebo for weight loss in persons with Type 2 Diabetes and a BMI above 27. The study drug will be a new Once Weekly Amylin Receptor or Once Weekly Tirzepatide (Mounjaro), alone or in combination versus placebo. Similar agents are currently being used successfully for diabetes and obesity.  

Investigational Drug: 

Amylin Receptor Agonist, a new once weekly injectable weight loss medication to reduce appetite and body weight alone or in combination with Tirzepatide (Mounjaro), compared with placebo.

To Qualify: Persons age 18 or older diagnosed with Type 2 Diabetes with an HBA1c from 7.0 to 10.5, treated with diet and exercise alone or with a stable dose of meformin, with or without an SGLT2 inhibitor for at least 3 months prior to study. 

Goal: To assess investigational medications on weight loss in diabetic persons with obesity with or without risk factors.